While nearly 85% of RAS-driven cancers are KRAS mutants (6), HRAS and NRAS share approximately 82% to 90% of the amino acid (aa) sequence with KRAS (24), with the majority of variance occurring within the C-terminal region (Fig. 1A). Here, HRAS is linked to cancer.